JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Elenco Azioni・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Chiusa

SettoreSettore sanitario

24.75 0.32

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.66

Massimo

24.81

Metriche Chiave
By Trading Economics
Entrata	51M -129M
Vendite	207M
Margine di Profitto	-62.319
Dipendenti	1,371
EBITDA	8.8M -105M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+111.71% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	379M 2.4B
Apertura precedente	24.43
Chiusura precedente	24.75

Notizie sul Sentiment di mercato

By Acuity

19%

81%

35 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.76 / 39.24 Supporto e resistenza

Ultragenyx Pharmaceutical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mag 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mag 2026, 18:37 UTC

I principali Market Mover

Senseonic Shares Slide on Underwritten Offering Price

1 mag 2026, 16:46 UTC

I principali Market Mover

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mag 2026, 19:57 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mag 2026, 15:24 UTC

Utili

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mag 2026, 12:46 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mag 2026, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 20:42 UTC

Utili

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mag 2026, 19:18 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mag 2026, 19:13 UTC

Discorsi di Mercato

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mag 2026, 18:36 UTC

Utili

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 18:28 UTC

Utili

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mag 2026, 18:27 UTC

Discorsi di Mercato

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mag 2026, 18:14 UTC

Acquisizioni, Fusioni, Takeovers

Barclays Completes Acquisition of Best Egg

1 mag 2026, 18:04 UTC

Utili

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mag 2026, 17:43 UTC

Discorsi di Mercato

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mag 2026, 17:37 UTC

Discorsi di Mercato

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mag 2026, 17:30 UTC

Discorsi di Mercato

Utili

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mag 2026, 17:28 UTC

Discorsi di Mercato

Utili

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mag 2026, 17:21 UTC

Discorsi di Mercato

Utili

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mag 2026, 17:19 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mag 2026, 16:38 UTC

Discorsi di Mercato

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mag 2026, 16:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Ultragenyx Pharmaceutical Inc Previsione

Obiettivo di Prezzo

By TipRanks

111.71% in crescita

Previsioni per 12 mesi

Media 52.44 USD 111.71%

Alto 84 USD

Basso 25 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ultragenyx Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a Ultragenyx Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.76 / 39.24Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

35 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.